According to AstraZeneca, the Medicines and Healthcare Products Regulatory Agency(MHRA) has approved a low-carbon version of a triple combination pressurised metred dose (pMDI) inhaler designed for adults with moderate-to-severe chronic obstructive pulmonary disease (COPD).

The propellant hydrofluoroalkane-134a (HFA-134a), which has a high Global Warming Potential (GWP), is currently used in the budesonide/glycopyrronium/formoterol fumarate inhaler (marketed under the Trixeo Aerosphere brand).
With a GWP 99.9% lower than the original propellant, the authorised next-generation propellant hydrofluoroolefin-1234ze (HFO-1234ze(E)) is a fluorinated gas.
By making this modification, the triple combination inhaler’s carbon footprint is on par with that of propellant-free dry powder low-Carbon inhalers.
